Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login

Who we are

The membership of the British Biosimilars Association (BBA) comprises a wide group of manufacturers active in the development and production of biosimilar medicines including those who have successfully manufactured and sold them in the UK for the past ten years.

The members of the BBA ensure access for UK patients to biosimilar medicines approved to the same high standards of safety, quality and efficacy as the originator or reference products. As industry experts, we partner with patients’ representatives, healthcare professionals, regulators and payers to increase understanding and to drive a sustainable environment for the development, production and optimised use of biosimilar medicines across the UK.

Our challenge

We have a market in the UK where off patent generic medicines fulfil over three-quarters1 of all prescriptions for conventional medicines, delivering some of the lowest medicines prices in Europe as a result.

For biosimilar medicines however, despite prolonged use in the UK since 2006, subsequent NICE guidance and resources as well as recent NHS England support for the appropriate use of biosimilars, there remains a surprisingly low up-take in using biosimilar treatments in the UK compared to a number of other European countries8 and variance between different Trusts in England.9

As of 2014, eight out of the top ten medicines sold in Europe were biological medicines.12 Given five of the top seven biologics will lose patent by 2020, biosimilars may play a profound role in the future of healthcare, allowing more patients to benefit from effective and proven treatment options.5 

Demand for important but expensive biologic medicines is expected to increase, further stretching payer expenditures and thus limiting patient access. By introducing competition, biosimilar medicines offer more choices at competitive prices thereby providing the opportunity to increase patient access without increasing overall spending. Furthermore, competition from  biosimilars can free up resources to help fund  new medical breakthroughs, with competition motivating producers of patent protected medicines to develop innovative products – driving the 'virtuous circle' of innovation and contributing to the financial sustainability of EU healthcare systems2.

We expect to see this virtuous circle develop in the UK in the next few years due to the loss of patent exclusivity on key molecules, combined with a rapidly developing biosimilar pipeline, resulting in multiple drug launches in long-term and life-saving therapeutic areas such as rheumatoid arthritis, cancer treatments and diabetes. The biosimilar market is therefore set to grow, providing the opportunity to improve access for patients to life transforming biological medicines and potentially saving the NHS hundreds of millions of pounds6,7 at a time when the NHS is looking to find £22bn in efficiency savings by 2020.10

For example, data based on 2010 usage of human growth hormone (hGH) at The North Central London Formulary and Medicines Management Group at University College London Hospitals NHS Trust suggests, annual cost savings in excess of £200,000 per annum are possible from a single centre if all patients were switched from originator hGH3 to biosimilar hGH . Savings generated through biosimilars can be reallocated in the same disease area to help fund access to recent innovative products or help fund access in other disease areas.4

Our approach and activities

The British Biosimilars Association is dedicated to furthering confidence in and education on the benefits of biosimilars for the NHS, patients and health care professionals. To this end we set out clear policy positions on a range of topics to advance the understanding and rapid adoption of biosimilar medicines and sign- post stakeholders to a range of authoritative resources in support of this goal. 

We have produced resource materials on the following important biosimilar topics:

•    Extrapolation
•    Sustainable pricing, procurement and reimbursement
•    Interchangeability
•    Switching
•    Patient access

We will continuously update our materials in response to this rapidly changing environment.

We have worked alongside NHS England , NICE, the MHRA and professional groups and other industry colleagues including ABPI, and other key stakeholders in developing materials such as the production of ‘What is a biosimilar?’ We participate actively in education programmes such as the NHS England biosimilar national and regional meetings. We have regular dialogue with patient and health professional bodies advocating accurate and transparent information on biosimilars.

Members

Accord

Biogen

Boeringher Ingelheim

Fresenius Kabi

Mylan

Napp

Sandoz

Teva

1 NHS Digital, Prescriptions Dispensed in the Community, Statistics for England - 2005-2015. Available here 
2 IMS, Delivering on the Potential for Biosimilar Medicines, 1st March 2016. Available here
3 Drug appraisal. Assessing the efficacy and safety of Omnitrope, The British Journal of Clinical Pharmacy 2010; 2:298-301
4 GfK EGA Sustainability Study 2014 September 9, Pg. 36
5 AbrahamJ et al. Developing oncology biosimilars: an essential approach for the future. Semin Oncol 2013:40 (Suppl 1): S5-S24

Delivering on the Potential of Biosimilar Medicines The Role of Functioning Competitive Markets, IMS, March 2016. Available here

7  Improving efficiency and resource allocation in future cancer care, OHE, September 2016. Available here

8 Assessing biosimilar uptake and competition in European markets, IMS Institute for Healthcare Informatics, October 2014. Available here

9 Medicines Optimisation dashboard on infliximab. Available here

10 NHS England, Five Year Forward View, October 2014. Available here

11 NHS Digital, Statistics available here

12 IMS Health, MIDAS, MAT, Rx bound. Europe doesn’t include Russia and Turkey, June 2014

 

 

77%
1
We have a market in the UK where generic and biosimilar medicines fulfil nearly three-quarters of all prescriptions for conventional medicines.

Our team

Kavya Gopal

Chair of the British Biosimilars Association

Andrew Roberts

Vice Chair of the BBA

Warwick Smith

Director General

Jeremy Durrant

Communications Director

Ania Swirski

Biosimilars Manager

Kavya Gopal

Chair of the British Biosimilars Association

Kavya Gopal is the current chair of the British Biosimilars Association (BBA) as well as Head of the Specialty Business for Sandoz UK. She has nearly 20 years of experience in the pharmaceutical industry leading successful teams in the US and in global roles for Novartis/Sandoz before moving to the UK earlier this year. 

She began her career in commercial analytics at GlaxoWellcome and has worked across multiple therapy areas in marketing, sales, operations and strategy.  Her breadth of expertise covers originator pharmaceuticals and generic medicines, including a deep knowledge of biosimilars.  Kavyamholds a degree in Chemistry from UNC-Chapel Hill and an MBA from INSEAD.

Andrew Roberts

Andrew Roberts

Vice Chair of the BBA

Andrew is Director of Market Access & Communications at Napp Pharmaceuticals Ltd and holds the position of Vice Chair of the BBA. Based in Cambridge, Andrew has almost 30 years’ experience in the Pharmaceutical and Life Sciences sector in the UK, US and EU having undertaken roles in sales management, marketing, communications and corporate affairs. For the past 15 years he has held senior positions within Market access and Health Policy, supporting the development of innovative approaches for how healthcare providers and the life sciences industry can collaborate effectively.

Kavya GopalWarwick Smith

Warwick Smith

Director General

Warwick Smith is the Director-General of the British Generic Manufacturers Association and the British Biosimilars Association (BBA). He is a member of the Board and Executive of the European Generic medicines Association (EGA), and was one of its Vice Presidents from 1995 to 2000.

Andrew RobertsJeremy Durrant

Jeremy Durrant

Communications Director

Jeremy Durrant heads up all internal and external communications activity on behalf of the British Biosimilars Association (BBA). He also is actively involved in stakeholder engagement, membership services, events and networking.

Warwick SmithAnia Swirski

Ania Swirski

Biosimilars Manager

Ania supports the BBA’s engagement with NHS England, NICE, MHRA and other relevant bodies and stakeholders to increase understanding of biosimilar medicines through information, guidance and partnership working.

Jeremy Durrant

Our members

Accord Healthcare

Biogen

Boehringer Ingelheim

Fresenius Kabi

Mylan

Napp Pharmaceuticals

Sandoz

Teva Pharmaceutical

Disclosure

Medicines for Europe disclosure request

As a national association member of Medicines for Europe, BGMA asks its members to disclose certain in-kind or actual transfers of value that have been made over the previous year to healthcare professionals, healthcare institutions or patient organisations.

Some BGMA (and BBA) members already voluntarily disclose this information through their membership of other trade bodies; and so they do not need to report twice. Some BGMA members have chosen to post their disclosure record on their own website. And some members have opted to post their return on the BGMA website.

As such, BGMA confirms that the following companies have opted to make a disclosure return on the BGMA website:

Company name Reporting a nil return or a transfer in value? Type of transfer of value Explanation Value or payment (£) Total amount transfers of value (£)
Rivopharm UK Ltd Nil return NA NA NA 0
Bowmed Ibisqus Ltd Transfer of value Third party organised congress NHS Pharmaceutical Quality Assurance & Technical Services Symposium 225.00 225.00
Aspire Pharma Limited Transfer of value Fees for service and consultancy to HCP Professional services from HCP 1 32,424.00
Transfer of value Fees for service and consultancy to HCP Professional services from HCP 1 3,432.00
Transfer of value Fee to healthcare organisation Attendance of event with company stand 600.00
Transfer of value Fee to healthcare organisation Attendance of event with company stand 250.00
Transfer of value Fee to healthcare organisation Attendance of event with company stand 240.00 36,946.00